Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Oct;39(10):2309–2315. doi: 10.1128/aac.39.10.2309

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.

C M Horton 1, M N Dudley 1, S Kaul 1, K H Mayer 1, K Squires 1, L Dunkle 1, R Anderson 1
PMCID: PMC162934  PMID: 8619587

Abstract

The population pharmacokinetics and bioavailability of oral stavudine (d4T; 2',3'-dideoxy-3'-deoxythymidine) was determined in 81 patients with AIDS or AIDS-related complex (ARC) enrolled in phase I and phase I/II dose-ranging trials. Each patient underwent inpatient pharmacokinetic studies following administration of the first oral stavudine dose; 59 patients were restudied after chronic therapy for an average of 19 days. Thirty-three of these patients also received a single intravenous stavudine dose prior to starting an oral regimen. A two-compartment model with first-order absorption and elimination was used as the structural pharmacokinetic model. A basic model provided the following population parameter estimates (interpatient variability expressed in parentheses as percent coefficient of variation): clearance/bioavailability = 30.9 (24.5%) liters/h; volume of distribution/bioavailability = 8.42 (not modeled) liters; volume of distribution at steady state/bioavailability = 68.9 (105%) liters; intercompartmental clearance/bioavailability = 12.4 (26%) liters/h; and first-order absorption rate constant = 1.32 (78.9%) liters/h. In the subset of 33 patients receiving both intravenous and oral doses, the bioavailability of stavudine was estimated to be 99.1% (18.5%). Total body weight, stage of disease (AIDS versus ARC), and an oral stavudine dose of > or = 200 mg were found to have a statistically significant but a clinically marginal effect on the estimate of the oral clearance of stavudine. This analysis shows the high degree of bioavailability of stavudine in patients with AIDS and ARC and the relatively low degree of interpatient variability in oral drug clearance compared with those of other nucleosides. Population pharmacokinetic analysis is a useful tool for assessing the combined effects of several patient variables on the pharmacokinetic properties of drugs in human immunodeficiency virus-infected patients.

Full Text

The Full Text of this article is available as a PDF (233.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. August E. M., Marongiu M. E., Lin T. S., Prusoff W. H. Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus. Biochem Pharmacol. 1988 Dec 1;37(23):4419–4422. doi: 10.1016/0006-2952(88)90655-7. [DOI] [PubMed] [Google Scholar]
  2. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., Vandeputte M. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun. 1987 Jan 15;142(1):128–134. doi: 10.1016/0006-291x(87)90460-8. [DOI] [PubMed] [Google Scholar]
  3. Balis F. M., Pizzo P. A., Butler K. M., Hawkins M. E., Brouwers P., Husson R. N., Jacobsen F., Blaney S. M., Gress J., Jarosinski P. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis. 1992 Jan;165(1):99–104. doi: 10.1093/infdis/165.1.99. [DOI] [PubMed] [Google Scholar]
  4. Balis F. M., Pizzo P. A., Murphy R. F., Eddy J., Jarosinski P. F., Falloon J., Broder S., Poplack D. G. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med. 1989 Feb 15;110(4):279–285. doi: 10.7326/0003-4819-110-4-279. [DOI] [PubMed] [Google Scholar]
  5. Balzarini J., Herdewijn P., De Clercq E. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem. 1989 Apr 15;264(11):6127–6133. [PubMed] [Google Scholar]
  6. Browne M. J., Mayer K. H., Chafee S. B., Dudley M. N., Posner M. R., Steinberg S. M., Graham K. K., Geletko S. M., Zinner S. H., Denman S. L. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993 Jan;167(1):21–29. doi: 10.1093/infdis/167.1.21. [DOI] [PubMed] [Google Scholar]
  7. Drusano G. L., Yuen G. J., Lambert J. S., Seidlin M., Dolin R., Valentine F. T. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial. Ann Intern Med. 1992 Apr 1;116(7):562–566. doi: 10.7326/0003-4819-116-7-562. [DOI] [PubMed] [Google Scholar]
  8. Drusano G. L., Yuen G. J., Morse G., Cooley T. P., Seidlin M., Lambert J. S., Liebman H. A., Valentine F. T., Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. Antimicrob Agents Chemother. 1992 Jun;36(6):1280–1283. doi: 10.1128/aac.36.6.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dudley M. N. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis. 1995 Mar;171 (Suppl 2):S99–112. doi: 10.1093/infdis/171.supplement_2.s99. [DOI] [PubMed] [Google Scholar]
  10. Dudley M. N., Graham K. K., Kaul S., Geletko S., Dunkle L., Browne M., Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis. 1992 Sep;166(3):480–485. doi: 10.1093/infdis/166.3.480. [DOI] [PubMed] [Google Scholar]
  11. Janiszewski J. S., Mulvana D. E., Kaul S., Dandekar K. A., Barbhaiya R. H. High-performance liquid chromatographic determination of 2',3'-didehydro-3'-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine. J Chromatogr. 1992 May 20;577(1):151–156. doi: 10.1016/0378-4347(92)80611-s. [DOI] [PubMed] [Google Scholar]
  12. Jarvis S. M. Characterization of sodium-dependent nucleoside transport in rabbit intestinal brush-border membrane vesicles. Biochim Biophys Acta. 1989 Feb 13;979(1):132–138. doi: 10.1016/0005-2736(89)90533-6. [DOI] [PubMed] [Google Scholar]
  13. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  14. Mandema J. W., Verotta D., Sheiner L. B. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992 Oct;20(5):511–528. doi: 10.1007/BF01061469. [DOI] [PubMed] [Google Scholar]
  15. Murray H. W., Squires K. E., Weiss W., Sledz S., Sacks H. S., Hassett J., Cross A., Anderson R. E., Dunkle L. M. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis. 1995 Mar;171 (Suppl 2):S123–S130. doi: 10.1093/infdis/171.supplement_2.s123. [DOI] [PubMed] [Google Scholar]
  16. Petersen E. A., Ramírez-Ronda C. H., Hardy W. D., Schwartz R., Sacks H. S., Follansbee S., Peterson D. M., Cross A., Anderson R. E., Dunkle L. M. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis. 1995 Mar;171 (Suppl 2):S131–S139. doi: 10.1093/infdis/171.supplement_2.s131. [DOI] [PubMed] [Google Scholar]
  17. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis. 1995 Mar;171 (Suppl 2):S113–S117. doi: 10.1093/infdis/171.supplement_2.s113. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES